TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21239021

Group type: EXPERIMENTAL
Intervention: Prostate specific antigen screening
Number of subjects: 0
Study: 19386869

Group type: EXPERIMENTAL
Intervention: Lidocaine 1% with epinephrine (1:100,000)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Bupivacaine 0.5%
Number of subjects: 12
Study: 17694489

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extra interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complex interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simple interventions
Number of subjects: 0
Study: 15009866

Group type: EXPERIMENTAL
Intervention: Flecainide (2 mg/kg as a 30-minute IV infusion) before electrical cardioversion
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo (100 mL IV infusion of 5% glucose) 30 minutes before electrical cardioversion
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 11587988

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone 500 microg twice daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 20
Study: 9861787

Group type: EXPERIMENTAL
Intervention: Model for identification and resolution of medication problems
Number of subjects: 0
Study: 7988630

Group type: EXPERIMENTAL
Intervention: Dihydrotachysterol preparations (capsules and oral solution)
Number of subjects: 48

Group type: COMPARATOR
Intervention: A.T.10 oral solution
Number of subjects: 48
Study: 2924483

Group type: EXPERIMENTAL
Intervention: Plating by AO principles
Number of subjects: 59

Group type: COMPARATOR
Intervention: External fixation with the one‐half pin technique
Number of subjects: 59
Study: 29884231

Group type: EXPERIMENTAL
Intervention: Clonidine (75μg every 3rd hour up to a maximum of 4 doses, then 75μg twice daily until delirium free for 2 days, discharge or a maximum of 7 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 28601270

Group type: EXPERIMENTAL
Intervention: Patient-Controlled Analgesia
Number of subjects: 636

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 636
Study: 25865041

Group type: EXPERIMENTAL
Intervention: Procalcitonin level measurement before and after TACE
Number of subjects: 42

Group type: COMPARATOR
Intervention: Antibiotic prophylaxis started 24 hours pre intervention and for 5 days after
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Laboratory investigations including CBC, neutrophil count, C-reactive protein and ESR
Number of subjects: 42
Study: 22918936

Group type: EXPERIMENTAL
Intervention: Training of the nondominant upper extremity
Number of subjects: 26

Group type: COMPARATOR
Intervention: No training (control)
Number of subjects: 26
Study: 20961566

Group type: EXPERIMENTAL
Intervention: Daily nutritional supplementation for 6 months followed by daily GH therapy for 12 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Observation for 6 months followed by daily GH therapy for 12 months
Number of subjects: 20
Study: 18705808

Group type: EXPERIMENTAL
Intervention: MBCP only
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: MBCP combined with irradiated cancellous bone
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: MBCP combined with intraoral autogenous bone
Number of subjects: 52
Study: 16401526

Group type: EXPERIMENTAL
Intervention: Manual acupressure with lavender oil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manual acupressure group
Number of subjects: 0
Study: 15319021

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Risperidone plus psychostimulant
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study: 11167054

Group type: EXPERIMENTAL
Intervention: Virtual representation of the body
Number of subjects: 0

Group type: COMPARATOR
Intervention: No virtual representation of the body
Number of subjects: 0
Study: 9451582

Group type: EXPERIMENTAL
Intervention: Conditioning group received a 90‐dB white noise unconditioned stimulus (UCS) paired with a frame‐lit rectangle (CS+).
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group received non‐contingent presentations of the noise and the two rectangles (CS-).
Number of subjects: 20
Study: 8103031

Group type: EXPERIMENTAL
Intervention: Pneumatic intermittent impulse device
Number of subjects: 37

Group type: COMPARATOR
Intervention: Modified impulse device (control)
Number of subjects: 37
Study: 3092851

Group type: EXPERIMENTAL
Intervention: Oral verapamil (120 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 30031369

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Modified Cognitive Processing Therapy (SMART-CPT)
Number of subjects: 74
Study: 26707905

Group type: EXPERIMENTAL
Intervention: Low AMH (<1.00 ng/mL; n = 124)
Number of subjects: 1228

Group type: EXPERIMENTAL
Intervention: Normal AMH (1.00-3.5 ng/mL; n = 595)
Number of subjects: 1228

Group type: EXPERIMENTAL
Intervention: High AMH (>3.5 ng/mL; n = 483)
Number of subjects: 1228

Group type: COMPARATOR
Intervention: Low or high AMH levels compared to normal AMH
Number of subjects: 1228

Group type: EXPERIMENTAL
Intervention: hCG-detected pregnancy loss
Number of subjects: 1228
Study: 24372829

Group type: EXPERIMENTAL
Intervention: Metoclopramide nasal spray 20 mg
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Metoclopramide nasal spray 10 mg
Number of subjects: 89

Group type: COMPARATOR
Intervention: Oral metoclopramide 10 mg
Number of subjects: 89
Study: 22877799

Group type: EXPERIMENTAL
Intervention: Defibrillation Testing (DT)
Number of subjects: 2500

Group type: COMPARATOR
Intervention: No Defibrillation Testing (No DT)
Number of subjects: 2500
Study: 20737520

Group type: EXPERIMENTAL
Intervention: 10 mg escitalopram
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 18656869

Group type: EXPERIMENTAL
Intervention: Continuous compartment pressure monitoring
Number of subjects: 109

Group type: COMPARATOR
Intervention: Clinical monitoring (historical control)
Number of subjects: 109
Study: 15920197

Group type: EXPERIMENTAL
Intervention: Conventional propofol-lidocaine mixtures with 20 mg lidocaine
Number of subjects: 75

Group type: COMPARATOR
Intervention: Propofol-MCT/LCT with saline
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Propofol-MCT/LCT with 20 mg lidocaine
Number of subjects: 75
Study: 12727037

Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate (OTFC)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Immediate release morphine sulfate (MSIR)
Number of subjects: 134
Study: 10738874

Group type: EXPERIMENTAL
Intervention: Use of a tourniquet
Number of subjects: 65

Group type: COMPARATOR
Intervention: Without the use of a tourniquet
Number of subjects: 65
Study: 9366661

Group type: EXPERIMENTAL
Intervention: Assertive Community Treatment (ACT) program
Number of subjects: 152

Group type: COMPARATOR
Intervention: Usual community services
Number of subjects: 152
Study: 1552711

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEPO) therapy
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg orally) after baseline values
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg orally) after correction of hematocrit
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Correction of hematocrit
Number of subjects: 8
Study: 3895043

Group type: EXPERIMENTAL
Intervention: Anterior lesser curve seromyotomy with posterior truncal vagotomy (AS + PT)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Proximal gastric vagotomy (PGV)
Number of subjects: 84
Study: 30973386

Group type: EXPERIMENTAL
Intervention: Gradient boosting model
Number of subjects: 90785

Group type: COMPARATOR
Intervention: CARES model
Number of subjects: 90785

Group type: COMPARATOR
Intervention: ASA-PS model
Number of subjects: 90785
Study: 29753637

Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 mg administered orally once daily (with dose reductions to 40 mg or 20 mg for adverse events)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 mg administered orally once daily
Number of subjects: 96
Study: 27065462

Group type: EXPERIMENTAL
Intervention: Low Glycemic Index (LGI) diet
Number of subjects: 50
Study: 24237610

Group type: COMPARATOR
Intervention: EP42675 (1-10 mg, single ascending doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: EP42675 (5 mg, single dose) + Aspirin (100 mg) + Clopidogrel (75 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: EP42675 (5 mg, second dose) + UFH (30 or 60 IU kg(‐1))
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EP42675 (5 mg, single dose)
Number of subjects: 0
Study: 22982083

Group type: EXPERIMENTAL
Intervention: Combined CBT for pain and insomnia
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: CBT for pain
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: CBT for insomnia
Number of subjects: 21

Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 21
Study: 19910928

Group type: EXPERIMENTAL
Intervention: Perindopril, hydrochlorothiazide (HCTZ), or indapamide (INDA) for 12 weeks
Number of subjects: 94
Study: 18595216

Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 10917

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10917
Study: 15959362

Group type: EXPERIMENTAL
Intervention: X STOP interspinous process decompression system
Number of subjects: 191

Group type: COMPARATOR
Intervention: Control (nonoperative treatment)
Number of subjects: 191
Study: 12030727

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 6 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 12
Study: 9849982

Group type: EXPERIMENTAL
Intervention: 0.1 ml intradermal (i.d.) PVRV
Number of subjects: 190

Group type: COMPARATOR
Intervention: 0.5 ml intramuscular (i.m.) PVRV
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Both i.d. and i.m. vaccinations
Number of subjects: 190
Study: 7852216

Group type: EXPERIMENTAL
Intervention: recombinant erythropoietin (rhEPO) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 3214852

Group type: EXPERIMENTAL
Intervention: Combination of 1.0 mM copper and 2.0 mM hexetidine
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control (glucose rinse)
Number of subjects: 4
Study: 31918233

Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 29197021

Group type: EXPERIMENTAL
Intervention: EPVL plus ESWL
Number of subjects: 153

Group type: COMPARATOR
Intervention: ESWL alone
Number of subjects: 153
Study: 27091735

Group type: EXPERIMENTAL
Intervention: C-arm computed tomography (CACT)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Angiography (control)
Number of subjects: 57
Study: 24917648

Group type: EXPERIMENTAL
Intervention: PEMFs (pulsed electromagnetic fields) 4 hours per day for 60 days starting within 3 days after operation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 30
Study: 23747945

Group type: EXPERIMENTAL
Intervention: 1.0mg fluoride tablet daily
Number of subjects: 217

Group type: COMPARATOR
Intervention: Placebo (Control Group)
Number of subjects: 217
Study: 21816067

Group type: EXPERIMENTAL
Intervention: Prone 12 o'clock position (PP)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Left lateral 6 o'clock position (LLP)
Number of subjects: 150
Study: 19287920

Group type: EXPERIMENTAL
Intervention: Total face mask (TFM)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Facial mask (FM)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nasal mask (NM)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pressure levels (low and moderate-to-high)
Number of subjects: 24
Study: 16709309

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Micronised fenofibrate 200 mg/day
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Combination treatment (Atorvastatin + Fenofibrate)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Atorvastatin and Combination treatment
Number of subjects: 186
Study: 15540755

Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Solifenacin 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11401659

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 9224960

Group type: EXPERIMENTAL
Intervention: 2 x 10(6) IU/m2 of IFN-beta
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 4 x 10(6) IU/m2 of IFN-beta
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 49
Study: 8492101

Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2b therapy for 1 year
Number of subjects: 11

Group type: COMPARATOR
Intervention: No therapy for 1 year
Number of subjects: 11
Study: 6428307

Group type: EXPERIMENTAL
Intervention: Rosoxacin (300 mg oral dose)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Ampicillin (3.5 g) plus Probenecid (1 g)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Rosoxacin
Number of subjects: 287

Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 287
Study: 30817010

Group type: EXPERIMENTAL
Intervention: PNFplus writing
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: PNF
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: EW
Number of subjects: 250

Group type: COMPARATOR
Intervention: Attention control feedback
Number of subjects: 250
Study: 30201029

Group type: EXPERIMENTAL
Intervention: Thread-embedding acupuncture (TEA)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sham thread-embedding acupuncture (STEA)
Number of subjects: 70
Study: 27280960

Group type: EXPERIMENTAL
Intervention: Psychoeducational website (UTSMed) accessed within 4 months after baseline survey.
Number of subjects: 1236

Group type: COMPARATOR
Intervention: Control group (no access to UTSMed).
Number of subjects: 1236
Study: 25315665

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 15 mg/week
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 26
Study: 22752356

Group type: EXPERIMENTAL
Intervention: Propofol infusion
Number of subjects: 12

Group type: COMPARATOR
Intervention: No propofol infusion
Number of subjects: 12
Study: 20131039

Group type: EXPERIMENTAL
Intervention: Gan-Pi regulatory needling (GPRN)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional Western medicine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Blank group (untreated)
Number of subjects: 90
Study: 17493508

Group type: EXPERIMENTAL
Intervention: Cilazapril 2.5-5.0 mg/day (n=70)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Enalapril 10-20 mg/day (n=82)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Perindopril 4-8 mg/day (n=73)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Imidapril 10-20 mg/day (n=76)
Number of subjects: 301
Study: 17375736

Group type: EXPERIMENTAL
Intervention: Oral desensitization (OD) for milk allergy
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Oral desensitization (OD) for egg allergy
Number of subjects: 150

Group type: COMPARATOR
Intervention: Avoidance diet (A) for milk allergy
Number of subjects: 150

Group type: COMPARATOR
Intervention: Avoidance diet (A) for egg allergy
Number of subjects: 150
Study: 15037408

Group type: EXPERIMENTAL
Intervention: 50 mg DHEA
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 200 mg DHEA
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 12903416

Group type: EXPERIMENTAL
Intervention: Glutamine dipeptide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 8958491

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% with adrenaline 5 micrograms mL‐1 (group II)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% with adrenaline 1.66 micrograms mL‐1 (group III)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bupivacaine 0.25% plain (group I)
Number of subjects: 60
Study: 1484671

Group type: EXPERIMENTAL
Intervention: one‐piece Staar Model AA‐4203 silicone intraocular lens (IOL) implanted through a 3.2‐millimeter incision
Number of subjects: 112

Group type: COMPARATOR
Intervention: one‐piece polymethylmethacrylate IOL implanted through a 6.0‐millimeter incision
Number of subjects: 112
Study: 3883504

Group type: EXPERIMENTAL
Intervention: oral etoposide (VePe-sid) 300 mg/m2 on days 1 and 2 for 6 cycles
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: oral etoposide plus cyclophosphamide 300 mg/m2 IV on days 1 and 2 for 6 cycles
Number of subjects: 325

Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: oral etoposide
Number of subjects: 325
Study: 31415133

Group type: EXPERIMENTAL
Intervention: Individual treatment (3 hours paediatrician + 4 hours dietician)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Group treatment (35 hours with a multidisciplinary team)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 74
Study: 28428892

Group type: EXPERIMENTAL
Intervention: Enhanced rehabilitation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 100
Study: 25735985

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO2) at 2.4 standard atmosphere, FI O2 = 1.0, for 90 minutes
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control conditions (ambient pressure, FI O2 = 0.21)
Number of subjects: 17
Study: 23303198

Group type: EXPERIMENTAL
Intervention: Olmesartan (40 mg/day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Telmisartan (80 mg/day)
Number of subjects: 36
Study: 21768063

Group type: EXPERIMENTAL
Intervention: Testing with feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testing without feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Restudying
Number of subjects: 0
Study: 19465426

Group type: EXPERIMENTAL
Intervention: FOLFOX4 until progression (arm A)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: FOLFOX7 for six cycles, maintenance without oxaliplatin for 12 cycles, and reintroduction of FOLFOX7 (arm B)
Number of subjects: 63
Study: 16920847

Group type: EXPERIMENTAL
Intervention: Lignan complex (500 mg/d of SDG)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (low-fat muffin without lignan complex)
Number of subjects: 22
Study: 12908850

Group type: EXPERIMENTAL
Intervention: Interferon-beta-1a (Avonex and Rebif)
Number of subjects: 2819

Group type: EXPERIMENTAL
Intervention: Rebif 44 microg three times weekly
Number of subjects: 2819

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2819

Group type: EXPERIMENTAL
Intervention: Interferon-beta-1a
Number of subjects: 2819
Study: 10999649

Group type: EXPERIMENTAL
Intervention: Continuous transdermal GTN therapy (0.6 mg/hour)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sublingual GTN (0.6 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Incubation with 22 nM GTN
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Incubation with 100 microM GTN
Number of subjects: 18

Group type: COMPARATOR
Intervention: Normal saline (as a control)
Number of subjects: 18
Study: 9360173

Group type: EXPERIMENTAL
Intervention: Manual border tracing by two observers or twice by the same observer
Number of subjects: 25
Study: 1588488

Group type: EXPERIMENTAL
Intervention: HIV gp 160 antigens for immunization
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: HIV gp 160 antigens with or without vaccinia vector
Number of subjects: 25
Study: 3903779

Group type: EXPERIMENTAL
Intervention: 0.1% betamethasone plus 2% fusidic acid
Number of subjects: 81

Group type: COMPARATOR
Intervention: 0.1% betamethasone alone
Number of subjects: 81
Study: 31522033

Group type: EXPERIMENTAL
Intervention: Brivanib 800 mg daily
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Brivanib
Number of subjects: 595

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 595
Study: 30596749

Group type: EXPERIMENTAL
Intervention: Storytelling intervention (two DVDs delivered three months apart)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Didactic intervention (one DVD)
Number of subjects: 160
Study: 27159952

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg/day)
Number of subjects: 62
Study: 25268340

Group type: EXPERIMENTAL
Intervention: Rhinovirus infection
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: RSV infection
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Influenza infection
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Bacterial infection
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: hMPV infection
Number of subjects: 170
Study: 22892747

Group type: EXPERIMENTAL
Intervention: VPro StreamClean System (VSS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional needle irrigation
Number of subjects: 20
Study: 20107464

Group type: EXPERIMENTAL
Intervention: Healthy Home Offerings via the Mealtime Environment (HOME) program
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 44
Study: 17283363

Group type: EXPERIMENTAL
Intervention: Fludarabine plus cyclophosphamide (FC)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Fludarabine (FL)
Number of subjects: 235
Study: 16115131

Group type: EXPERIMENTAL
Intervention: lenograstim (10 microg/kg BW per day)
Number of subjects: 501

Group type: COMPARATOR
Intervention: filgrastim (10 microg/kg BW per day)
Number of subjects: 501
Study: 11794192

Group type: EXPERIMENTAL
Intervention: Warfarin (adjusted to produce an INR of 1.4 to 2.8)
Number of subjects: 2206

Group type: COMPARATOR
Intervention: Aspirin (325 mg per day)
Number of subjects: 2206

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 2206

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 2206
Study: 9893779

Group type: EXPERIMENTAL
Intervention: Breathe Right (BR) device
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control night (without BR)
Number of subjects: 10
Study: 8034071

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/d)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normal cycling women (control group)
Number of subjects: 14
Study: 2661445

Group type: EXPERIMENTAL
Intervention: Vitajet
Number of subjects: 6